Assessment of Pharmacokinetics and Bioavailability of Carbon-14 ([14C])-Labelled Oxytocin

NCT02911480 | Withdrawn Phase 1

• 1 other identifier: OXB-001
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The current study is designed as a phase I multiple dose study to evaluate the pharmacokinetics and bioavailability of \[14C\]-labelled oxytocin in healthy women.

Conditions

Healthy Women of Child Bearing Potential

Outcome Measures

Primary Outcomes (5)

• pharmacokinetics (PK) parameter for oxytocin: maximum plasma concentration (Cmax)

  Day 1, predose and at t=3, 7, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 480 minutes.

• pharmacokinetics (PK) parameter for oxytocin: time to Cmax (tmax)

  Day 1, predose and at t=3, 7, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 480 minutes.

• pharmacokinetics (PK) parameter for oxytocin: area under the plasma-concentration time curve (AUC)

  Day 1, predose and at t=3, 7, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 480 minutes.

• pharmacokinetics (PK) parameter for oxytocin: terminal half-life (t1/2)

  Day 1, predose and at t=3, 7, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 480 minutes.

• pharmacokinetics (PK) parameter for oxytocin: bioavailability (F)

  Day 1, predose and at t=3, 7, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 480 minutes.

Study Arms (5)

oxytocin intravenous 0.1 IU

EXPERIMENTAL

single dose of 0.1 International Units (IU) intravenous (IV) oxytocin

Drug: Oxytocin

oxytocin intravenous 1 IU

EXPERIMENTAL

single dose of 1 IU IV oxytocin

Drug: Oxytocin

oxytocin intravenous 10 IU

EXPERIMENTAL

single dose of 10 IU IV oxytocin

Drug: Oxytocin

oxytocin tablet 20 IU

EXPERIMENTAL

single dose of 20 IU tablet oxytocin

Drug: Oxytocin

oxytocin tablet 200 IU

EXPERIMENTAL

single dose of 200 IU tablet oxytocin

Drug: Oxytocin

Interventions

Oxytocin DRUG

oxytocin intravenous 0.1 IU; oxytocin intravenous 1 IU; oxytocin intravenous 10 IU; oxytocin tablet 20 IU; oxytocin tablet 200 IU

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Non-smoking women of child bearing potential (WOCBP)
• Body mass index (BMI) between ≥ 18.0 and ≤ 30.0 kg/m2
• Subject must voluntarily sign a written informed consent agreement approved by the Independent Ethics Committee (IEC) after explanation of the nature and objectives of the study and before any study specific procedure
• Subject must be in good physical and mental health as judged by the Investigator based on evaluation of medical and gynecological history, physical examination, clinical laboratory, ECG, and vital signs data
• Subject is willing and able to comply with all conditions and requirements of the study

You may not qualify if:

• Lactation and/or pregnancy in the previous 6 months before screening, whichever is applicable
• Intention to become pregnant during the study or within 1 months after the follow up visit
• History of, or existing thromboembolic, cardiovascular or cerebrovascular disorder
• Treatment for any major psychiatric disorder in the previous 12 months or use of antidepressant medication before screening
• Any clinically significant abnormality following review of medical history, laboratory results and physical examination at screening as judged by the Investigator
• Conditions or disorders that might affect the absorption, distribution, metabolism or excretion of the study drugs
• Contraindications for the use of oxytocin
• Hypersensitivity to the active substances or to any of the excipients of the investigational product or reference therapy
• Present use or use within 30 days before the start of the study medication of one or more of the following medications: antihypertensive drugs, anti-coagulant therapy, medication that could affect myometrial contractility, sex steroids, prostaglandins and its analogues, inhalation anesthetics, vasoconstrictors/sympathomimetics and caudal anesthetics, vasopressin-like drugs
• Use of any prescribed or over-the-counter medication within 14 days before Day 1
• Administration of any other investigational drug within 3 months before Day 1 or participation in 3 or more clinical trials in the 10 months before Day 1
• Loss of more than 500 milliliters (mL) blood during the 3 months before Day 1, or intention to donate blood in the 3 months after completing the study
• Subjects with a positive test result for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) at screening
• Subjects with a history of alcohol or drug abuse or with a positive result at screening, for tests of alcohol intake or drugs of abuse

Sponsors & Collaborators

• Oxytone Bioscience BV: lead

MeSH Terms

Interventions

Oxytocin

Intervention Hierarchy (Ancestors)

Pituitary Hormones, Posterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 16, 2016
• First Posted: September 22, 2016
• Study Start: April 1, 2016
• Primary Completion: February 1, 2017
• Study Completion: August 31, 2017
• Last Updated: April 6, 2018

Record last verified: 2018-04